ERBB2 and breast cancer: A phase III trial of T-DXd involving patients with HER2-low metastatic BC recently concluded that trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician’s choice of chemotherapy (i.e., NCT03734029/DESTINY-Breast04) (8).